NabazenilAlternative Names: AC 42574; HGP 6; SP 175
Latest Information Update: 08 Feb 2008
At a glance
- Originator HG Pars
- Class Antiepileptic drugs; Neuroprotectants
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Epilepsy
Most Recent Events
- 21 Mar 2000 No-Development-Reported for Epilepsy in USA (Unknown route)